Cardiovascular Systems to Webcast Fiscal 2013 Third-Quarter Earnings Conference Call Wednesday, May 1 Live Webcast at 3:45 p.m. CT (4:45 p.m. ET) Business Wire ST. PAUL, Minn. -- April 24, 2013 Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII) will host a live webcast of its fiscal 2013 third-quarter conference call on Wednesday, May 1, 2013, at 3:45 p.m. CT (4:45 p.m. ET). David Martin, president and chief executive officer, and Larry Betterley, chief financial officer, will discuss the company’s results for its fiscal third quarter ended March 31, 2013, and its financial outlook. The company will issue a post-market earnings release prior to the call on May 1. To access the live webcast, go to the investor section of the company’s website, www.csi360.com, on the day of the conference call and click on the webcast icon. A webcast replay will be available beginning at 5:45 p.m. CT the same day. To participate in the conference call, dial (888) 713-4205 and enter 48810662. Please dial in at least 10 minutes prior to the call. To pre-register for the call, log on to the following website: https://www.theconferencingservice.com/prereg/key.process?key=PHYDR44WB. When joining the call, pre-registered participants can enter their PIN code, and other participants can press *0 to reach the operator, or wait on the line for operator assistance. If you do not have access to the Internet and want to listen to an audio replay of the conference call, dial (888) 286-8010 and enter access number 46269911. The audio replay will be available beginning at 5:45 p.m. CT on Wednesday, May 1, 2013, through 11 p.m. CT on Wednesday, May 8, 2013. About Cardiovascular Systems, Inc. Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company’s Orbital Atherectomy Systems treat calcified and fibrotic plaque in arterial vessels throughout the leg in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. The U.S. Food and Drug Administration (“FDA”) granted 510(k) clearance for the use of the Diamondback Orbital Atherectomy System in August 2007. To date, over 100,000 of CSI’s devices have been sold to institutions across the United States. CSI recently completed its ORBIT II Investigational Device Exemption clinical trial to evaluate the safety and effectiveness of its orbital technology in treating coronary arteries and submitted its Premarket Approval (“PMA”) application to the FDA on March 15, 2013. The coronary system is limited by federal law to investigational use and is currently not commercially available in the United States. For more information, visit the company’s website at www.csi360.com. Contact: Cardiovascular Systems, Inc. Investor Relations, 651-259-2800 firstname.lastname@example.org or Padilla Speer Beardsley Inc. Marian Briggs, 612-455-1742 email@example.com or Matt Sullivan, 612-455-1709 firstname.lastname@example.org
Cardiovascular Systems to Webcast Fiscal 2013 Third-Quarter Earnings Conference Call Wednesday, May 1
Press spacebar to pause and continue. Press esc to stop.